Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A) . An homogeneous population of high affinity binding sites for [ 3 H]Ro 41-1049 is found in membrane preparations from human frontal cortex and placenta ( K d values of 16.5 and 64.4 nM, respectively) In Vivo Ro 41-1049 (1-50 mg/kg; intraperitoneal injection; for 3 hours; Sprague-Dawley rats) treatment inhibits dopamine metabolite formation and increases dopamine levels in a dose-dependent fashion. Pretreatment with Ro 41-1049 (20 mg/kg) significantly increases dopamine formation following L-dopa administration (100 mg/kg IP) while decreasing formation of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats (200-240 g)Dosage: 1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 50 mg/kg Administration: Intraperitoneal injection; for 3 hours Result: Inhibited dopamine metabolite formation and increased dopamine levels in a dose-dependent fashion. Pretreatment with the concentration of 20 mg/kg significantly increased dopamine formation following L-dopa administration while decreasing formation of DOPAC and HVA. Form:Solid IC50& Target:MAO-A